Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL4234896 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL13459830 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL19513553 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18379765 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 1.00 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28487532 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL9281280 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28299858 | 0.99 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25522 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144880-A1 | SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-05-28 | — | — | US | claimed |
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| CN-114761428-B | Anti-hemagglutinin antibodies and methods of use thereof | 瑞泽恩制药公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4744662-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING ERRy INHIBITOR AS ACTIVE INGREDIENT | Industry Foundation of Chonnam National University (KR) | 2026-05-20 | — | — | EP | claimed |
| CN-122055148-A | Conjugates, compositions and methods for treating influenza | 珀杜研究基金会 | 2026-05-15 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| WO-2002000201-A2 | METHOD FOR PREPARING A COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | claimed |
| WO-2001097792-A2 | NEURAMINIDASE INHIBITORS IN THE TREATMENT OF EQUINE INFLUENZA VIRUS INFECTION | GLAXOSMITHKLINE K K (GB) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097804-A1 | MEDICAMENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2001-12-27 | — | — | WO | claimed |
| WO-2001054729-A1 | TREATMENT OF NEUROPSYCHIATRIC DISEASE WITH PROTEASE AND NEURAMINIDASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001038314-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038312-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001037837-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038313-A1 | 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-05-31 | — | — | WO | claimed |
| WO-2001019322-A2 | USE OF CSAIDS IN RHINOVIRUS INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-22 | — | — | WO | claimed |
| EP-1059283-A1 | Process for preparing neuraminidase inhibitor ro-64-0796 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | claimed |